Literature DB >> 11129106

Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection.

W D Le1, J Jankovic, W Xie, S H Appel.   

Abstract

Pramipexole and several other dopamine agonists have been recently demonstrated to have neuroprotective effects in vitro and in vivo. We report here that pramipexole can protect DAergic cell line MES 23.5 against dopamine (DA), 6-hydroxydopamine (6-OHDA), and hydrogen peroxide (H2O2)-induced cytotoxicity in vitro possibly through antioxidant effects, and such neuroprotection could not be blocked by selective D2 or D3 antagonists. Incubation with pramipexole (5-20 microM) in MES 23.5 cell cultures increased cellular levels of glutathione (GSH), and elevated glutathione peroxidase (GSH-Px) and catalase activities, but only marginally enhanced SOD activity. Pretreatment with D2 or D3 antagonists did not block the stimulating effects of pramipexole on the cellular levels of GSH, and on the activities of GSH-Px and catalase in MES 23.5 cells. These results indicate that pramipexole's neuroprotective effects are likely associated with its antioxidant property independent of D2/D3 receptor activation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11129106     DOI: 10.1007/s007020070030

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  29 in total

1.  Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines.

Authors:  Venugopalan D Nair; C Warren Olanow; Stuart C Sealfon
Journal:  Biochem J       Date:  2003-07-01       Impact factor: 3.857

Review 2.  Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment?

Authors:  Pengfei Yang; Joel S Perlmutter; Tammie L S Benzinger; John C Morris; Jinbin Xu
Journal:  Ageing Res Rev       Date:  2019-11-22       Impact factor: 10.895

Review 3.  L-DOPA treatment from the viewpoint of neuroprotection. Possible mechanism of specific and progressive dopaminergic neuronal death in Parkinson's disease.

Authors:  Norio Ogawa; Masato Asanuma; Ikuko Miyazaki; Francisco J Diaz-Corrales; Ko Miyoshi
Journal:  J Neurol       Date:  2005-10       Impact factor: 4.849

4.  Pramipexole protects against H2O2-induced PC12 cell death.

Authors:  Yoshiko Fujita; Yuki Izawa; Nermin Ali; Yasuhisa Kanematsu; Koichiro Tsuchiya; Shuichi Hamano; Toshiaki Tamaki; Masanori Yoshizumi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-12-16       Impact factor: 3.000

5.  Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetic efficiency.

Authors:  Kambiz N Alavian; Steven I Dworetzky; Laura Bonanni; Ping Zhang; Silvio Sacchetti; Maria A Mariggio; Marco Onofrj; Astrid Thomas; Hongmei Li; Jamie E Mangold; Armando P Signore; Ulrike Demarco; Damon R Demady; Panah Nabili; Emma Lazrove; Peter J S Smith; Valentin K Gribkoff; Elizabeth A Jonas
Journal:  Brain Res       Date:  2012-01-28       Impact factor: 3.252

Review 6.  Are dopamine receptor agonists neuroprotective in Parkinson's disease?

Authors:  W D Le; J Jankovic
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

7.  A novel PINK1- and PARK2-dependent protective neuroimmune pathway in lethal sepsis.

Authors:  Rui Kang; Ling Zeng; Yangchun Xie; Zhengwen Yan; Borong Zhou; Lizhi Cao; Daniel J Klionsky; Kevin J Tracey; Jianhua Li; Haichao Wang; Timothy R Billiar; Jianxin Jiang; Daolin Tang
Journal:  Autophagy       Date:  2016-10-18       Impact factor: 16.016

8.  Mitochondria-targeted antioxidant effects of S(-) and R(+) pramipexole.

Authors:  Giulia Ferrari-Toninelli; Giuseppina Maccarinelli; Daniela Uberti; Erich Buerger; Maurizio Memo
Journal:  BMC Pharmacol       Date:  2010-02-05

Review 9.  Dopaminergic agonists: possible neurorescue drugs endowed with independent and synergistic multisites of action.

Authors:  Daniela Uberti; Irene Bianchi; Luca Olivari; Giulia Ferrari-Toninelli; Sara A Bonini; Maurizio Memo
Journal:  Neurochem Res       Date:  2007-05-08       Impact factor: 3.996

Review 10.  Neuroprotective strategies in Parkinson's disease : an update on progress.

Authors:  Silvia Mandel; Edna Grünblatt; Peter Riederer; Manfred Gerlach; Yona Levites; Moussa B H Youdim
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.